Tivantinib for Second-line Treatment of Advanced MET-High Hepatocellular Carcinoma: A Phase 3, Randomized, Placebo-Controlled Study (METIV-HCC)

Rimassa, L; Assenat, E; Peck-Radosavljevic, M; Pracht, M; Zagonel, V; Mathurin, P; Rota-Caremoli, E; Porta, C; Daniele, B; Bolondi, L; Mazzaferro, V; Harris, W; Damjanov, N; Pastorelli, D; Reig, M; Knox, J; Negri, F; Trojan, J; López López, C; Personeni, N; Decaens, T; Dupuy, M; Sieghart, W; Abbadessa, G; Schwartz, B; Lamar, M; Goldberg, T; Shuster, D; Santoro, A; Bruix, J.